US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

264.88

-14.1385-5.07%

Volume:193.46K

Turnover:51.80M

Market Cap:496.52M

PE:- -

High:274.71

Open:265.00

Low:260.01

Close:279.02

52wk High:341.93

52wk Low:74.95

Shares:1.87M

Float Shares:1.87M

Volume Ratio:1.31

T/O Rate:10.32%

Dividend:1.00

Dividend Rate:0.38%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Sector Update: Healthcare Stocks Mixed Premarket Wednesday

MT Newswires Live

Metropolis Healthcare Allots 66,312 Shares Under 2020 RSU Plan

Health Care Select Sector SPDR: Pivot points

Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance

Avicanna Expands MyMedi.ca Platform with Integrated Medical Cannabis Program in Canadian Healthcare

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioLife Solutions (BLFS) and Corbus Pharmaceuticals (CRBP)

Autolus Receives FDA Regenerative Medicine Advanced Therapy Designation for Obecabtagene Autoleucel

MT Newswires Live

Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Waters (WAT) and Amgen (AMGN)

Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Pharvaris (PHVS) and Zimmer Biomet Holdings (ZBH)

RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/LABU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":264.8815,"timestamp":1789058199777,"preClose":279.02,"halted":0,"volume":193462,"delay":0,"changeRate":-0.05067199483907951,"floatShares":1874486,"shares":1874486,"eps":0,"marketStatus":"Trading","change":-14.1385,"latestTime":"09-10 12:36:39 EDT","open":265,"high":274.705,"low":260.01,"amount":51799657.50434001,"amplitude":0.052666,"askPrice":265.75,"askSize":30,"bidPrice":264.75,"bidSize":30,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":279.02,"sharesOutstanding":3074486,"nav":292.443,"aum":548181239.8,"dividendRate":0.003792,"bidAskSpread":0.003029,"preHourTrading":{"tag":"盘前","latestPrice":268.99,"preClose":279.02,"latestTime":"09:29 EDT","volume":1828,"amount":503835.0052,"timestamp":1789046962415,"change":-10.03,"changeRate":-0.035947,"amplitude":0.054249},"postHourTrading":{"tag":"盘后","latestPrice":278.58,"preClose":279.02,"latestTime":"19:59 EDT","volume":5408,"amount":1506106.6336,"timestamp":1788998373887,"change":-0.44,"changeRate":-0.001577,"amplitude":0.005304},"volumeRatio":1.313239,"impliedVol":0.9198,"impliedVolPercentile":0.5259},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1874486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.313239,"shares":1874486,"dividePrice":1.0045,"high":274.705,"amplitude":0.052666,"preClose":279.02,"low":260.01,"week52Low":74.95,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":264.8815,"eps":0,"divideRate":0.003792,"volume":193462,"delay":0,"ttmEps":0,"open":265,"prevYearClose":159.39,"prevWeekClose":303.55,"prevMonthClose":296.31,"prevQuarterClose":292.1,"fiveDayClose":311.81,"twentyDayClose":286.75,"sixtyDayClose":188.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666351825","title":"Sector Update: Healthcare Stocks Mixed Premarket Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2666351825","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666351825?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:16","pubTimestamp":1788959818,"startTime":"0","endTime":"0","summary":"Healthcare stocks were mixed premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF  0.4% higher and the iShares Biotechnology ETF  down 0.3%.InnovAge Holding  shares were up more than 10% after the company reported that it swung to earnings in fiscal Q4 amid stronger-than-expected sales growth.Seaport Therapeutics  stock was nearly 4% higher after the company said its phase 1 driving simulation trial of GlyphAllo met its primary endpoint, with the 375 mg dose showing no next-morning driving impairment versus placebo after multiple-day dosing.Evommune's  phase 2b trial of EVO756 to treat adults with moderate-to-severe atopic dermatitis didn't meet its primary and secondary endpoints in any of the doses studied, the company said. Evommune shares were down more than 8% pre-bell.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","INNV","BK4007","EVMN","LU0029874061.USD","LU0128526141.USD","SPTX","BK4139","BK4585","XLV","BK4196","IBB","XBI","BK4137","HCSG","LABU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666535154","title":"Metropolis Healthcare Allots 66,312 Shares Under 2020 RSU Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2666535154","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666535154?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:09","pubTimestamp":1788959383,"startTime":"0","endTime":"0","summary":"An update from Metropolis Healthcare Ltd. ( ($IN:METROPOLIS) ) is now available. Metropolis Healthcare has allotted 66,312 equity shares to employe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/metropolis-healthcare-allots-66312-shares-under-2020-rsu-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/metropolis-healthcare-allots-66312-shares-under-2020-rsu-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","LU0029874061.USD","LABU","XBI","BK4137","HCSG","XLV","BK4581","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666253364","title":"Health Care Select Sector SPDR: Pivot points","url":"https://stock-news.laohu8.com/highlight/detail?id=2666253364","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666253364?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:39","pubTimestamp":1788957543,"startTime":"0","endTime":"0","summary":"The following are the pivot points for the Health Care Select Sector SPDR (XLV). Pivot High: $167.94, Pivot Low: $166.13. These were calculated usi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/health-care-select-sector-spdr-pivot-points-thefly-news-138?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/health-care-select-sector-spdr-pivot-points-thefly-news-138?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4585","LABU","XLV","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666970533","title":"Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2666970533","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666970533?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:30","pubTimestamp":1788957000,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept.  09, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd.(NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358646/0/en/quantum-biopharma-ltd-nasdaq-qntm-receives-fda-clearance-to-begin-trials-for-historic-ms-treatment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","03160","ONEQ","JEPQ","QDTE","QID","TQQY","BK4007","NQmain","NVIW.SI","TM","QQQ","QQQM","BK4555","TQQQ","IYW","BK4099","QNTM","BK4588","GPIQ","FTEC","PSQ","SQQQ","MNQmain","QQQA","BK4585","TECS","NDX","03086",".IXIC","LABU","QQQY","QQQJ","BK4604","QYLG","QQQE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533180","title":"Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533180","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533180?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:30","pubTimestamp":1788957000,"startTime":"0","endTime":"0","summary":"Submission package includes Method Comparison Study, which delivered accuracy above 98%, sensitivity above 94%, and 100% specificity across three independent U.S. clinical sitesNEW YORK, Sept.  09, 20","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358636/0/en/intelligent-bio-solutions-submits-fda-510-k-package-for-intelligent-fingerprinting-drug-screening-system-seeking-u-s-market-clearance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666090538","title":"Avicanna Expands MyMedi.ca Platform with Integrated Medical Cannabis Program in Canadian Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2666090538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666090538?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:16","pubTimestamp":1788956189,"startTime":"0","endTime":"0","summary":"An announcement from Avicanna ( ($TSE:AVCN) ) is now available. Avicanna has launched the MyMedi.ca Integrated Healthcare Program in Canada to embe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/avicanna-expands-mymedi-ca-platform-with-integrated-medical-cannabis-program-in-canadian-healthcare?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/avicanna-expands-mymedi-ca-platform-with-integrated-medical-cannabis-program-in-canadian-healthcare?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MSOX","XLV","LU0128526141.USD","HCSG","BK4588","LU0029874061.USD","CNBS","MJ","TOKE","MSOS","WEED","BK4585","LABU","XBI","YOLO","BK4137","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666976533","title":"Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2666976533","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666976533?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:00","pubTimestamp":1788955200,"startTime":"0","endTime":"0","summary":"– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all establish","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358551/0/en/humacyte-announces-fda-authorization-extending-symvess-shelf-life-to-36-months.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","AV","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533142","title":"Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533142","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533142?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:00","pubTimestamp":1788955200,"startTime":"0","endTime":"0","summary":"Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apneaU.S. composition and methods of treatment patent granted covering IHL-42X with baseline exp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358577/0/en/incannex-healthcare-provides-corporate-update-on-clinical-progress-intellectual-property-and-capital-position.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128526141.USD","LABU","BK4585","HCSG","BK4581","XLV","BK4588","LU2065732104.USD","LU0029874061.USD","BK4137","BK4097","USRD","XBI","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666547538","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: BioLife Solutions (BLFS) and Corbus Pharmaceuticals (CRBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666547538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666547538?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:50","pubTimestamp":1788954637,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioLife Solutions (BLFS) and Corbus Pharmaceutical...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-biolife-solutions-blfs-and-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-biolife-solutions-blfs-and-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU1169589451.USD","XLV","LU0029874061.USD","LU0128526141.USD","BK4139","BK4198","BK4585","BLFS","CRBP","XBI","BK4137","LU1169590202.USD","HCSG","LABU","BK4581","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580908","title":"Autolus Receives FDA Regenerative Medicine Advanced Therapy Designation for Obecabtagene Autoleucel","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580908","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580908?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:42","pubTimestamp":1788954145,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics (AUTL) said Wednesday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation for obecabtagene autoleucel to treat systemic lupus e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IE00B7SZL793.SGD","LU1815336091.USD","LU0274383776.USD","LU2931357623.SGD","AUTL","BK4157","IE00B19Z4B17.USD","LABU","BK4585","BK4588","IE00B66KJ199.SGD","LU0757428866.USD","IE0031619046.USD","AEIS","LU2089985449.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666796587","title":"Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel","url":"https://stock-news.laohu8.com/highlight/detail?id=2666796587","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666796587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:15","pubTimestamp":1788952531,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics (AUTL) announced that the FDA has granted regenerative medicine advanced therapy, or RMAT, designation to obecabtagene autoleu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/autolus-therapeutics-granted-rmat-designation-for-obecabtagene-autoleucel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/autolus-therapeutics-granted-rmat-designation-for-obecabtagene-autoleucel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LENZ","AUTL","LABU","BK4139","BK4539","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666769587","title":"Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666769587","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666769587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:10","pubTimestamp":1788952232,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Collegium Pharmaceutical (COLL), Revolution Medicine...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-collegium-pharmaceutical-coll-revolution-medicines-rvmd-and-intellia-therapeutics-ntla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-collegium-pharmaceutical-coll-revolution-medicines-rvmd-and-intellia-therapeutics-ntla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IE00B4R5TH58.HKD","LU0889565916.HKD","COLL","BK4588","XBI","BK4556","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4007","LU0029874061.USD","BK4535","BK4137","CANC","IDNA","IE00BFTCPJ56.SGD","IE0009355771.USD","NTLA","RVMD","LU1861559042.SGD","IE00BJJMRZ35.SGD","LABU","XLV","BBH","PTH","HCSG","IE0009354923.USD","LU1861558580.USD","BK4585","LU0320765992.SGD","BK4581","LU0109394709.USD","IE0002141913.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666941587","title":"Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2666941587","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666941587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"Enrollment in LUMINA, the pivotal Phase 2 study of obe-cel in refractory lupus nephritis, is ongoingLONDON and GAITHERSBURG, Md., Sept.  09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358486/0/en/autolus-therapeutics-announces-fda-rmat-designation-granted-to-obe-cel-for-the-treatment-of-systemic-lupus-erythematosus-and-lupus-nephritis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4110","BK4139","LABU","BK4588","BK4007","SLE","BK4585","BK4077","BK4539","ACR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587949","title":"Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587949","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587949?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improve","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358458/0/en/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-trial-of-opgx-best1-and-successful-fda-type-c-meeting-with-potential-phase-3-dosing-in-2027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","NVIB","MEDX","GDOC","ARB","IDNA","LABU","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587934","title":"Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587934","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587934?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a n","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358488/0/en/rezolute-provides-update-on-fda-review-of-its-phase-3-sunrize-study-results-in-congenital-hyperinsulinism.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HI","LU2360032135.SGD","SOC","LU2125154778.USD","BK4588","LU0029874061.USD","BK4161","BK4585","LU0128526141.USD","LU2125154935.USD","LABU","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666458794","title":"X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2666458794","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666458794?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"BOSTON, Sept.  09, 2026  -- X4 Pharmaceuticals , a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10, 2026 at 9:30 a.m. ET. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations. About X4 Pharmaceuticals X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI in its first indication. The Company is currently conducting a global, pivotal Phase 3 clinical trial  evaluating mavorixafor in chron","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358482/0/en/x4-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-2026-wells-fargo-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0787776722.HKD","LU2361045086.USD","XBI","BK4559","LU0980610538.SGD","LU1506573853.SGD","LU0477156953.USD","BK4582","LU1267930227.SGD","LU0251142724.SGD","FTXO","LU0942090050.USD","LU1074936037.SGD","LU0029874061.USD","LU2461242641.AUD","LU0310800379.SGD","LU0320765489.SGD","PGF","LU0208291251.USD","IYF","LU0251131958.USD","LU0267386448.USD","LU0314106906.USD","LU1791807156.HKD","LU0708994859.HKD","TFNS","LU0640476718.USD","LU1668664300.SGD","KBWB","LU0310800965.SGD","LU0048573561.USD","LU0868494617.USD","LU0149725797.USD","LU0029864427.USD","LABU","LU0130517989.USD","LU0175139822.USD","LU0072461881.USD","XLV","LU2236285917.USD","LU0211328371.USD","HCSG","LU0417517546.SGD","LU1894683264.USD","BK4585","BK4504","IE000M9KFDE8.USD","LU0128525689.USD","BK4581","LU1267930490.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587822","title":"Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Waters (WAT) and Amgen (AMGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587822","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587822?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:50","pubTimestamp":1788951011,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Assembly Biosciences (ASMB), Waters (WAT) and Amge...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-assembly-biosciences-asmb-waters-wat-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-assembly-biosciences-asmb-waters-wat-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","GB00B4QBRK32.GBP","LU0347712357.USD","LU0889565916.HKD","LU2242646821.SGD","PJP","LU0868494617.USD","LU1061106388.HKD","LU2242652126.USD","LU0109394709.USD","IBBQ","LU0728928796.USD","LU2089984988.USD","BK4588","BIB","BK4585","IBB","PBE","LU2112291526.USD","XLV","AMGN","HCSG","IE0002141913.USD","BK4566","BK4139","IE00B2B36J28.USD","TBXU","LU0029874061.USD","LU2468319806.SGD","LU1983299246.USD","WAT","GB00B4LPDJ14.GBP","LU1721428933.USD","BK4533","LU0320765992.SGD","BK4581","LABU","LU2404859741.USD","SG9999001440.SGD","LU1023059063.AUD","ASMB","IE00B4R5TH58.HKD","LU0122379950.USD","LU2404859667.USD","IE00BJT1NW94.SGD","LU2413666699.HKD","LU0058720904.USD","BK4121","BBH","LU0690374961.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666828455","title":"Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2666828455","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666828455?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:30","pubTimestamp":1788949800,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358431/0/en/telix-to-present-at-the-morgan-stanley-24th-annual-global-healthcare-conference-and-h-c-wainwright-28th-annual-global-investment-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791710582.SGD","IAI","LU1989772923.USD","LU2089283258.USD","BK4588","LU0098860793.USD","LU2487616109.SGD","BK4504","HCSG","LU0128526141.USD","LU1244550494.USD","ASX","LU0390134368.USD","LU1732800096.USD","LU1074936037.SGD","LU1244550221.USD","LU0314104364.USD","BK4516","BK4534","LU1720051017.SGD","IE00BZ1G4Q59.USD","KBWB","BK4127","IE00BKVL7J92.USD","LU0557290698.USD","LU2347655156.SGD","LU0225283273.USD","BK4141","LU0158827948.USD","IE00B775SV38.USD","LU0795875086.SGD","LU0267386448.USD","TLX","XBI","XLV","LU1162221912.USD","BK4137","LU1668664300.SGD","LU0053666078.USD","LU0106831901.USD","LU0006306889.USD","LU1064131342.USD","LU0106261372.USD","LU2028103732.USD","LABU","LU1363072403.SGD","LU0158827781.USD","LU0234570918.USD","MS","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666582590","title":"Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Pharvaris (PHVS) and Zimmer Biomet Holdings (ZBH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666582590","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666582590?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:20","pubTimestamp":1788949241,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abbott Laboratories (ABT), Pharvaris (PHVS) and Zi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abbott-laboratories-abt-pharvaris-phvs-and-zimmer-biomet-holdings-zbh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abbott-laboratories-abt-pharvaris-phvs-and-zimmer-biomet-holdings-zbh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0432979614.USD","LU1201861249.SGD","LU0114720955.EUR","LU1267930573.SGD","LU0130102774.USD","LU1023059063.AUD","LU2089984988.USD","LU1670628061.USD","LU0211327993.USD","ZBH","BK4504","LU0234572021.USD","SGXZ23171101.USD","XLV","LU1691799644.USD","PJP","LU0882574055.USD","LU2211815571.USD","TMED","IHI","LABU","IE00B2B36J28.USD","IE00B19Z3581.USD","LU0310799852.SGD","LU0708994859.HKD","LU2133065610.SGD","LU0128526141.USD","LU2468319806.SGD","LU0211328371.USD","LU0648001328.SGD","IE0002270589.USD","IE00BJT1NW94.SGD","BK4007","LU1061106388.HKD","HCSG","ABT","BK4082","IE00B19Z3B42.SGD","LU1914381329.SGD","LU1989763690.USD","BK4592","LU0029864427.USD","LU0980610538.SGD","PHVS","LU0320765489.SGD","BK4585","XBI","LU0170899867.USD","LU2237957811.SGD","LU0889566641.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666582848","title":"RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2666582848","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666582848?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:00","pubTimestamp":1788948000,"startTime":"0","endTime":"0","summary":"LOS ANGELES, Sept.  09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358410/10985/en/radnet-inc-to-present-at-the-morgan-stanley-24th-annual-global-healthcare-conference-on-wednesday-september-16th-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874061.USD","XBI","BK4581","BK4196","XLV","HCSG","BK4137","LU0128526141.USD","BK4585","RDNT","BK4588","LU2065731478.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":3,"totalSize":412,"code":"91000000","status":"200"}]}}